Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Anthem Biosciences

ANTHEM
Mid Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Anthem Biosciences Share price and Fundamental Analysis

View All Details
View All Details
Anthem Biosciences Limited was originally incorporated as 'Anthem Biosciences Private Limited', dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to 'Anthem Biosciences Limited' and a Certificate of Incorporation upon the conversion was issued by RoC on December 10, 2024.
Company Incorporation2006
ChairmanNA
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
46,383
PE Ratio
102.72
Industry P/E
18.17
PEG Ratio
0
ROE
%
ROCE
%
ROA
0%
Total Debt (Cr)
0
Debt to Equity
Dividend Yield
0%
EPS
8.04
Book Value & P/B
44.05 x 18.75
Face Value
2
Outstanding Shares(Cr)
56.16
Current Ratio
EV to Sales
33.91

Included In

+More

Stock Returns

1 Week+10.04%
1 Month+12.97%
6 Months+12.97%
1 Year+12.97%
3 Years+12.97%
5 Years+12.97%
no_data

No Stocks

Smart Score

2.2
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone
PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Jul 25

Promoters : 74.69%

FIIs : 1.50%

DIIs : 3.35%

Public : 20.46%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in July 2025 Qtr
FII Shareholding Increased by 1.5% to 1.5% in July 2025 Qtr
DII Shareholding Increased by 3.35% to 3.35% in July 2025 Qtr
Promoter Shareholding Decreased by 2.54% to 74.69% in July 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Anthem Biosciences Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Anthem Biosciences Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Anthem Biosciences Limited was originally incorporated as 'Anthem Biosciences Private Limited', dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to 'Anthem Biosciences Limited' and a Certificate of Incorporation upon the conversion was issued by RoC on December 10, 2024.

The Company has been set up as a Life sciences/ Biotechnology based venture specialising in the manufacture of catalytic preparation, other organic compounds such as speciality organic molecules, biologically active peptides etc., which are high-value products used in drug, agrochemical and speciality chemicals industries.

The Company started operations at Unit I and set up a Custom Synthesis Plant with a capacity of 6 KL in year 2007. It commenced discovery biology services with a fermentation capacity of 2 KL in 2008. It expanded the Custom Synthesis Plant at Unit I increasing its capacity from 6 KL to 24 KL in 2010. It set up a high potent lab at Unit I - Bommasandra Facility in 2016. The Company was merged with Anthem Cellutions (India) Private Limited by acquiring 100% of its share capital in November, 2017. It set up a flow chemistry lab scale and solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1. It commenced operations of the Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL in 2018-19. In year 2020, Company started operations to biological unit 2 earmarked for a specific client. It expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL. In FY 2024, Company set up a wholly owned subsidiary Neoanthem Lifesciences Private Limited and commenced operations at Unit III for development in projects.

Company is planning an Offer for Sale by raising funds from public through IPO aggregating to Rs 3395 Cr Equity Shares.

Anthem Biosciences Share Price

Anthem Biosciences share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Anthem Biosciences Market Cap

Market capitalization of Anthem Biosciences indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Anthem Biosciences is valued compared to its competitors.

Anthem Biosciences PE Ratio

Anthem Biosciences PE ratio helps investors understand what is the market value of each stock compared to Anthem Biosciences 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Anthem Biosciences PEG Ratio

The PEG ratio of Anthem Biosciences evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Anthem Biosciences ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Anthem Biosciences generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Anthem Biosciences ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Anthem Biosciences in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Anthem Biosciences Total Debt

Total debt of Anthem Biosciences shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Anthem Biosciences Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Anthem Biosciences compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Anthem Biosciences CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Anthem Biosciences over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Anthem Biosciences Technical Analysis

Technical analysis of Anthem Biosciences helps investors get an insight into when they can enter or exit the stock. Key components of Anthem Biosciences Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Anthem Biosciences shares often struggle to rise above due to selling pressure.

Anthem Biosciences Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Anthem Biosciences ’s financial health and profitability.

Anthem Biosciences Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Anthem Biosciences Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Anthem Biosciences Financials

The financials of Anthem Biosciences provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Anthem Biosciences Profit and Loss Statements

The profit and loss statement of Anthem Biosciences highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Anthem Biosciences .

Anthem Biosciences Balance Sheet

The balance sheet presents a snapshot of Anthem Biosciences ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Anthem Biosciences Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.